ACCENDRA HEALTH INC.

Lobbying for ACCENDRA HEALTH INC.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 15, 2026

Expenses

$280,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Virginia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 5

S 4307
Protecting American Consumers from Robocalls Act
HR 2005
DMEPOS Relief Act of 2025
S 2951
Competitive Bidding Relief Act
HR 2902
SOAR Act of 2025
S 1406
SOAR Act of 2025

Lobbying activity 4

Health Issues

Issues related to patient access to home medical equipment and related reimbursement.

Medicare/Medicaid

Issues related to access to home medical equipment and related reimbursement (i.e., the "Diabetes Interventions Addressing Barriers to Enrollment, Technology, and Education Services [DIABETES] Act" (S. 4307) and the "DMEPOS Relief Act of 2025" [H.R. 2005, S. 2951]; and competitive bidding, the "Supplemental Oxygen Access Reform [SOAR] Act of 2025" [H.R. 2902, S. 1406]); promoting electronic prescribing platforms; and diabetes management and related durable medical equipment reimbursement channels.

Budget/Appropriations

FY 2027 Appropriations.

Veterans

CHAMPVA medical supply reimbursement.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.